Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adults. GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone palmitate is a dopamine‑serotonin antagonist used in chronic psychotic disorders. - Schizophrenia: maintenance therapy to reduce relapse and control psychotic symptoms. - Schizoaffective disorder: management of psychotic features alongside mood symptoms. - Maintenance after acute episode: provides sustained drug levels to support long‑term stability.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Weight gain: gradual increase in body weight. - Akathisia: inner restlessness or inability to stay still. - Drowsiness: somnolence or reduced alertness. - Constipation: decreased bowel movements. - Elevated prolactin: hormonal changes leading to menstrual disturbances or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Seizures: increased risk in susceptible individuals. - Orthostatic hypotension: sudden drop in blood pressure upon standing. - Hyperglycemia: elevated blood glucose levels. - Cardiovascular events: arrhythmias or myocardial infarction.

Before initiating therapy with Paliperidone Teva, clinicians should evaluate patient history and monitor for specific risks. - Cardiovascular disease: assess for history of arrhythmias or heart failure. - Metabolic disorders: monitor weight, glucose, and lipid profiles regularly. - Pregnancy: avoid use unless benefits outweigh potential fetal risks. - Breastfeeding: contraindicated as drug is excreted in milk. - Elderly patients: start at lower dose and observe for orthostatic hypotension. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone palmitate can interact with several medication classes, altering efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone levels and toxicity. - CNS depressants (e.g., benzodiazepines): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., carbamazepine): may reduce drug exposure, risking loss of efficacy. - Antihypertensives: additive orthostatic hypotension may occur. - Anticholinergic agents: may exacerbate cognitive side effects.